Alexa Trost

Alexa Trost supports clients with research and analysis that span a variety of healthcare sectors and stakeholders.

She applies a public and international health background to a broad range of client projects.

Prior to joining Avalere, Alexa interned with the National Institutes of Health, where she reviewed federal research grant applications to ensure compliance with subject rights and institutional requirements. Additionally, she supported the American Red Cross, where she worked on the Client Relations team to enhance the organization’s youth strategy and created materials for volunteers.

Alexa has a BA in public health and international and global studies from Elon University.

Authored Content

Immunization Information Systems (IIS), or immunization registries, are used across the US to provide consolidated and complete accounts of patient immunization history in a given city, state, or region.

Amid the continuing pandemic and calls for healthcare reform, the new administration seeks to confront the myriad public health issues facing our country today.

Globally and in the US, widespread vaccination has demonstrated medical, economic, and social value to both individuals and public health and has contributed to reductions in morbidity and mortality of certain diseases.

Tune into another episode of Get the Facts on COVID-19. In this segment, our vaccines experts discuss state COVID-19 vaccine distribution plans, distribution challenges, and what this space might look like as the vaccines become more widely available.

The convergence of the seasonal influenza and the current COVID-19 vaccines will merge several distribution considerations for a diverse group of stakeholders.

The November 2020 election is widely anticipated to have important implications for how the US responds to COVID-19.

Tune into another episode of Start Your Day with Avalere. In this segment, experts from our vaccines team discuss the general outlook for the vaccines marketplace and pipeline.

Vaccine development is at the forefront of global efforts to address the COVID-19 pandemic, with a rapidly growing pipeline of candidates that will expand the existing vaccine landscape.

Avalere analysis finds Medicare incurred $106.4 billion in 2016–2018 treating diseases potentially preventable with inline vaccines and select pipeline vaccine candidates. Those diseases also resulted in beneficiary costs of approximately $9.6 billion during the same time period.

On April 15, President Trump announced his intention to halt funding to the World Health Organization (WHO), pending an investigation into WHO’s response to the COVID-19 pandemic. WHO first declared the outbreak a Public Health Emergency of International Concern on January 30 and a global pandemic on March 11. A reduction in funding from the US could limit WHO’s COVID-19 response activities as well as its regular vaccine programming, including product prequalification, global surveillance, and ongoing efforts to strengthen health systems.

Since the 1980s, all 50 states have used immunization requirements as a condition of school entry to protect the public’s health from vaccine-preventable diseases.

Tune in as Avalere experts interview each other on hot topics in healthcare. In this discussion, Avalere Managing Director of Health Plans and Providers, Fred Bentley is interviewed by Alexa Trost, Associate, on the current state of value-based care across the health care landscape and critical steps post-acute care organizations needs to take to to succeed in this environment.